Psoriatic disease is an immune-driven condition where the body’s defense system mistakenly attacks healthy tissue, causing inflammation in the skin, joints, or both. It encompasses two closely related problems: psoriasis, which produces thick, scaly patches on the skin, and psoriatic arthritis, which causes painful, swollen joints. About 30% of people with psoriasis eventually develop joint involvement, making psoriatic disease a systemic condition that reaches well beyond the skin.
How the Immune System Drives Psoriatic Disease
In a healthy immune system, specialized cells called T cells identify and fight infections. In psoriatic disease, certain T cells become overactive and begin attacking the body’s own tissues. A specific group of these cells produces inflammatory signals that accelerate skin cell growth and inflame joint tissue. Skin cells that normally take about a month to mature and shed are pushed to the surface in just days, piling up into the raised, silvery plaques that define psoriasis.
The joint side of the disease follows a similar pattern. Immune cells flood into the lining of joints, the connective tissue where tendons attach to bone, and the sheaths surrounding tendons. Regulatory T cells, which normally keep the immune response in check, lose their ability to suppress inflammation in affected tissue. Researchers have also identified specific autoantibodies in the blood of people with psoriatic arthritis, present in roughly 85% of patients, further confirming that the immune system is actively targeting the body’s own proteins.
Genetics play a significant role. Carrying a gene variant called HLA-Cw6 increases the risk of developing psoriasis by tenfold in people of European descent. Another marker, HLA-B27, appears in 10 to 25% of people with psoriatic arthritis. But genes alone don’t cause the disease. Triggers like infections, physical injury, obesity, and changes in gut bacteria can push a genetically susceptible person into active disease.
What Psoriatic Disease Looks Like
Psoriatic disease shows up differently depending on which tissues are involved, and many people have overlapping symptoms across skin, nails, and joints.
On the skin, psoriasis typically appears as well-defined, raised patches covered with silvery-white scales. These plaques most commonly form on the elbows, knees, scalp, and lower back, though they can appear anywhere. The patches can itch, burn, or crack and bleed.
Nail changes are common and often overlooked. Small dents or pits across the nail surface, thickening of the nail, and separation of the nail from the nail bed are hallmarks of psoriatic nail disease. Nail involvement is one of the diagnostic criteria doctors use and can be an early signal that joint disease may follow.
Joint symptoms range from mild stiffness to severe, disabling pain. Two features are particularly distinctive. The first is dactylitis, sometimes called “sausage digits,” where an entire finger or toe swells uniformly so that individual joints are no longer visible. This affects roughly 50% of people with psoriatic arthritis. The swelling can be acutely painful with redness and heat, or it can settle into a chronic, non-tender puffiness that limits movement. The second hallmark is enthesitis, inflammation where tendons and ligaments attach to bone. This occurs in about 35% of patients and commonly strikes the Achilles tendon and the bottom of the foot near the heel. It can easily be mistaken for a sports injury or plantar fasciitis.
From Skin Disease to Joint Disease
Psoriasis typically appears first. In a population-based study tracking the progression, about 60% of people who developed psoriatic arthritis had skin symptoms before joint symptoms, while the remaining 40% developed both around the same time. Among those where psoriasis came first, the median time from skin diagnosis to joint diagnosis was roughly 10 years, though the range varied enormously. Some people transitioned within months, others after two decades.
This lag matters because early treatment of joint inflammation prevents permanent damage. Once erosion begins in a joint, it cannot be reversed. Recognizing the warning signs, particularly new joint stiffness, heel pain, or a swollen finger, gives people with existing psoriasis a meaningful head start on protecting their joints.
How Psoriatic Arthritis Is Diagnosed
There is no single blood test for psoriatic arthritis. Doctors use a classification system called the CASPAR criteria, which requires evidence of inflammatory joint disease plus at least 3 points from a checklist. Current psoriasis is worth 2 points. A history of psoriasis, a family history of psoriasis, dactylitis, new bone formation near joints, negative rheumatoid factor, and nail changes each count for 1 point. A negative rheumatoid factor is particularly useful because it helps distinguish psoriatic arthritis from rheumatoid arthritis, which can look similar on the surface.
Psoriatic Disease in Children
Children can develop psoriatic arthritis, and it looks somewhat different than the adult version. Young children are more likely to have inflammation in the small joints of the hands and feet and to develop dactylitis. Importantly, children with a positive antinuclear antibody (ANA) blood test face an increased risk of uveitis, a type of eye inflammation that can be painless and unnoticed until vision is affected. Regular eye exams with an ophthalmologist are a key part of monitoring for these children. Not all children with psoriatic arthritis have a visible skin rash, which can delay diagnosis.
Risks Beyond Skin and Joints
Psoriatic disease is not confined to the areas you can see and feel. The same inflammatory process that damages skin and joints affects blood vessels and metabolism. People with psoriasis are up to 50% more likely to develop cardiovascular disease compared to the general population, and the risk scales with severity. Those with severe psoriasis face up to three times the odds of heart attack, 60% higher odds of stroke, and 40% higher odds of dying from cardiovascular causes.
Traditional risk factors like high blood pressure, diabetes, high cholesterol, obesity, and smoking are also more common in people with psoriatic disease. In aggregate, more than half of psoriasis patients have at least one of these, yet they are frequently under-recognized and undertreated. Managing psoriatic disease effectively means paying attention to heart and metabolic health alongside skin and joints.
How Psoriatic Disease Is Treated
Treatment depends on how much skin, how many joints, and which specific features are involved. Mild skin-only psoriasis can often be managed with topical creams that calm inflammation and slow skin cell turnover. When the disease is more widespread or joints are affected, systemic treatments become necessary.
The biggest shift in treatment over the past two decades has been the development of biologic therapies, medications delivered by injection or infusion that block specific inflammatory signals. Several classes target different parts of the immune cascade. Some block a signal called TNF, which drives inflammation broadly. Others target signals called IL-17 or IL-23, which are more specifically involved in the skin and joint pathways of psoriatic disease. Biologics targeting TNF and IL-17 are particularly recommended when the spine, tendons, or peripheral joints are involved and haven’t responded to older medications.
A newer category of oral medications called JAK inhibitors works by interrupting the signaling pathways inside immune cells. Two have been approved for psoriatic arthritis, offering an alternative for people who prefer pills over injections or who haven’t responded to biologics. These treatments can improve joint pain, skin clearance, and physical function, though they require monitoring for side effects.
For many people, finding the right treatment involves trial and adjustment. What works well for skin may not fully control joint symptoms, and vice versa. The goal is to reduce inflammation enough to prevent permanent joint damage and keep skin clear, while maintaining the best possible quality of life.
Who Gets Psoriatic Disease
Globally, psoriatic arthritis affects roughly 112 out of every 100,000 adults, though rates vary sharply by region. Europe has the highest prevalence at about 188 per 100,000, followed by North America at 133 per 100,000. Rates in Asia (48 per 100,000) and South America (17 per 100,000) are considerably lower, likely reflecting a combination of genetic differences and variation in how the disease is diagnosed and recorded. The condition affects men and women at roughly equal rates and most commonly appears between the ages of 30 and 50, though it can start at any age.